Bill > HR6789

This bill, titled the "Federal Prisons Naloxone Access Act of 2025," mandates that the Bureau of Prisons (BOP), which oversees federal correctional facilities, must ensure the availability of opioid antagonists at all its facilities. An opioid antagonist is a medication, approved by the Food and Drug Administration (FDA), that can reverse the effects of an opioid overdose. The bill requires that adequate numbers of these opioid antagonist kits, which also include instructions on recognizing and responding to overdoses, be kept in various locations within each facility, including medical areas, staff breakrooms, and common areas where incarcerated individuals gather. These kits must be stored properly and securely, and importantly, incarcerated individuals must be able to access them to administer to someone experiencing an overdose. Furthermore, the BOP must provide annual training to both staff and incarcerated individuals on how to recognize overdose symptoms and administer the opioid antagonists, and any kits with expiration dates must be regularly checked for replacement. The bill also mandates documentation of each instance an opioid antagonist is administered and explicitly states that incarcerated individuals acting in good faith to administer these medications will not be held liable. Finally, the Director of the BOP is required to submit an annual report to Congress detailing the availability of these kits, overdose incidents, training numbers, and expired kits, with specific appropriations authorized for fiscal years 2026 through 2028 to cover the costs of training, purchasing, and maintaining these life-saving supplies.

Justice

https://www.congress.gov/bill/119th-congress/house-bill/6789/all-info